Physician profile
Michael I Danto
NPI 1659368777
$2,514.45
in general payments reported to CMS, 2019-2025
24 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $705 · 2021: $519 · 2022: $254 · 2023: $233 · 2024: $72.33 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $471.14 | 2019-2021 | |
| Bioventus LLC | $464.54 | 2019-2021 | |
| Depuy Synthes Sales INC. | $247.40 | 2020-2025 | Monovisc |
| Spr Therapeutics, INC | $225.58 | 2023-2025 | Sprint Pns System |
| Forte Bio-Pharma LLC | $160.65 | 2021-2023 | Prolate, Nalocet |
| Stimwave Technologies Incorporated | $144.69 | 2020 | |
| Arbor Pharmaceuticals, INC. | $136.76 | 2019-2020 | |
| Ge Healthcare | $104.50 | 2023 | |
| Boston Scientific Corporation | $85.82 | 2019 | |
| Radius Health, INC. | $66.46 | 2019-2021 | |
| Abbvie INC. | $55.15 | 2022 | |
| Stryker Corporation | $48.62 | 2021 | |
| Ibsa Pharma INC. | $45.08 | 2025 | Tirosint, Licart, Flector |
| Pfizer INC. | $41.77 | 2019-2020 | |
| Allergan, INC. | $38.82 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $35.56 | 2019-2024 | Gel-One Cross-Linked Hyaluronate |
| Painteq LLC | $26.68 | 2023 | Painteq |
| Scilex Pharmaceuticals INC. | $20.41 | 2019 | |
| Saxum Surgical, INC. | $18.73 | 2022 | |
| Nevro Corp. | $16.99 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.60 | 2019 | |
| Horizon Therapeutics Plc | $15.79 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.30 | 2022 | |
| Biodelivery Sciences International, INC. | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Danto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.